Explore

Companies

Drugs

VivoSeq

About·Data Management·Terms·Privacy

Stay informed

Oncology/B Acute Lymphoblastic Leukemia With T(9;22)(q34.1;q11.2); BCR-ABL1

Oncology

B Acute Lymphoblastic Leukemia With T(9;22)(q34.1;q11.2); BCR-ABL1

Pipeline Programs↗

Active Trials↗

Companies Involved↗

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is an emerging landscape with 20 programs across 11 companies. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

12/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical2

Inotuzumab Ozogamicin

Wyeth-Lederle Vaccines

Mercaptopurine

Stason

Phase 1

No programs

Phase 27

Rituximab

Roche

Vincristine

Eli Lilly

Doxorubicin

Pfizer

Etoposide

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Phase 311

Cyclophosphamide

Baxter Healthcare Corporation

Cytarabine

Teva

Dexamethasone

Aspen Global Incorporated

Methotrexate

Jazz Pharmaceuticals

Blinatumomab

Amgen

Approved

No programs

Analysis

Modality Breakdown

65%

Small molecule

13 of 20 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

clinical trials

Recruiting2 · 67%

Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT04530565·348 enrolled

Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07224100·33 enrolled

Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT01371630·276 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)